Annexon Inc Ordinary Shares
North American company
Times are shown in GMT-5, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
This stock can be held in:
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexon's product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases.
Latest ANNX News
Currently there are no news & analysis articles for this instrument. Visit our news hub for the latest investment news from ii and Alliance News